Abstract Submission Guidelines

In addition to keynote speakers and workshops, the Lysosomal Disease Summit programme will feature research presentations selected from top-scoring abstracts submitted globally. This is an opportunity for scientists and professionals in lysosomal disease to present innovative research and contribute to the scientific dialogue shaping the field.

Submit an Abstract

Key Dates

Abstract Submissions Open
1 April 2026 (00:00 AEST)

Abstract Submission Deadline
1 July 2026 (00:00 AEST)

Acceptance Notifications Sent
22 July 2026

Submission Overview

All abstracts submitted by the deadline will undergo blinded peer review by the Lysosomal Disease Summit Programme Committee and will be considered for oral and/or poster presentation.

Abstracts may be edited or withdrawn at any time prior to the submission deadline. After the deadline, all submissions are considered final and may not be modified or withdrawn.

Presentation Expectations

The first (presenting) author is expected to attend the Summit and present the abstract if selected.

Oral presenters will receive a discounted registration rate.

All presenters must register for the Summit and cover their own travel and accommodation.

Abstracts must be submitted with the full intention of presenting if accepted.

Abstract Categories

  • Basic or Translational Scientific Research
    • Disease mechanisms, pathology, biomarkers, natural history, etc.
  • Clinical Applications
    • Clinical trials, outcomes research, case reports or case series
  • Social, Ethical and Legal Issues (SELI) / Public Health and Policy
    • Including newborn screening, population health, AI, and machine learning

Abstract Requirements

Length: Maximum 500 words. Images and figures are not permitted.

Authors: Maximum 25 authors per submission (no exceptions).

Disclosure Requirements

All first authors will be required to complete a disclosure prior to the Summit.

Once submitted, disclosures will apply across all abstracts associated with that author.

Additional details will be provided to accepted authors.

First Author Policy

The first author is designated as the presenting author.

Ensure the first author listed is the individual who will present.

Author order and names will be published exactly as submitted.

First authors cannot be changed once programme materials are finalised.

Review & Selection

Abstracts will be evaluated through a blinded peer review process based on scientific merit, originality, and relevance to lysosomal diseases.

Final placement (oral or poster) will be determined by the Programme Committee.

Registration

Submitting an abstract does not constitute registration. To present at the Summit, all presenters must register for the meeting and cover travel and accommodation costs.

Oral presenters will receive a 50% registration discount via a non-transferable code upon acceptance.

Scholarships

A limited number of scholarships will be available. Further details will be provided separately.

Technical Support

For questions related to abstract submission, please contact . Due to time zone differences, please allow up to 24 hours for a response.